Reaction
Treatment Delayed reporting signals
As of the last recalculation, Treatment Delayed appears in 1,596 FAERS reports alongside 20 co-occurring drug terms. The strongest observed disproportionality signal is CENEGERMIN-BKBJ (PRR 101.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Cenegermin-Bkbj | 89 | 101.6 | 102.3 |
| Infliximab-Dyyb | 179 | 89.8 | 90.4 |
| Lanreotide Acetate | 21 | 35.4 | 35.5 |
| Alteplase | 25 | 22.0 | 22.1 |
| Selinexor | 9 | 13.6 | 13.6 |
| Eptinezumab-Jjmr | 9 | 13.0 | 13.0 |
| Irinotecan Hydrochloride | 11 | 11.2 | 11.2 |
| Carboxymethylcellulose Sodium | 7 | 9.8 | 9.8 |
| Infliximab | 141 | 9.1 | 9.1 |
| Prednisolone Acetate | 7 | 8.9 | 8.9 |
| Benralizumab | 13 | 8.5 | 8.5 |
| Leucovorin Calcium | 12 | 8.2 | 8.2 |
| Cladribine | 6 | 8.2 | 8.2 |
| Fam-Trastuzumab Deruxtecan-Nxki | 6 | 7.8 | 7.8 |
| Ravulizumab | 8 | 7.8 | 7.8 |
| Ixekizumab | 16 | 5.7 | 5.7 |
| Lifitegrast | 7 | 5.6 | 5.6 |
| Lenalidomide | 154 | 5.2 | 5.2 |
| Isotretinoin | 13 | 3.4 | 3.4 |
| Esketamine Hydrochloride | 4 | 2.9 | 2.9 |